Loading stock data…
$21.45-0.05 (-0.23%)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.
STAAR Surgical Company in the Healthcare sector is trading at $21.45 with a market capitalization of $1.2B. Wall Street consensus targets $28.00 (9 analysts), implying a +30.5% move over the next 12 months. The stock is currently 40% below its 52-week high of $35.87, remaining 9.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $93.53M | $93.52M↑ | $57.80M↓ | $94.73M↑ | $44.32M |
| Gross Profit | $69.73M↑ | $68.86M↑ | $43.74M↓ | $77.88M↑ | $32.80M |
| Operating Income | $10.10M↓ | $17.40M↑ | -$10.94M↓ | $24.44M↑ | -$24.72M |
| Net Income | $8.06M↑ | $5.21M↑ | -$18.31M↓ | $8.88M↑ | -$16.81M |
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens p...